Navigation Links
Allergies lower risk of low- and high-grade glioma
Date:2/6/2011

PHILADELPHIA The more allergies one has, the lower the risk of developing low- and high-grade glioma, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Researchers from the University of Illinois at Chicago, used self-reported data on medically diagnosed allergies and antihistamine use for 419 patents with glioma and 612 cancer-free patients from Duke University and NorthShore University HealthSystem. Controls had no history of brain tumors or any cancers, and did not have a history of neurodegenerative disease.

"Other studies have found a correlation between allergies and glioma risk," said Bridget McCarthy, Ph.D., a research associate professor of epidemiology at the University of Illinois at Chicago School of Public Health. "In this study we confirmed that allergies are protective and found that the more allergies one has, the more protected he or she is."

Participants completed a web-based or telephone survey and were asked if they were medically diagnosed with allergies or asthma at least two years prior to the survey, and if so, the age of diagnosis. In addition, they were asked to indicate the number of individual allergies within each of the following groupings: seasonal, pet, medication, food and other.

Included in the survey were details on regular medication usage two years or more prior to the survey, and information on specific medication brands, frequency and duration of usage.

Allergies appeared to be protective and provided a reduced risk for those with who have a higher number and more types of allergies, according to the study results. Age of allergy diagnosis and years since diagnosis were not associated with glioma risk. In addition, antihistamine use, including diphenhydramine hydrochloride (a possible neurocarcinogen), did not appear to affect glioma risk separately from the effects of allergies.

"Our study confirms that there is a relationship between the immune system of allergy sufferers and glioma risk," said McCarthy. "A comprehensive study of allergies and antihistamine use with standardized questions and biological markers is essential to further delineate the biological mechanism that may be involved in brain tumor development."


'/>"/>

Contact: Natalie Poole
Natalie.Poole@aacr.org
267-646-0619
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Allergies and wheezing illnesses in childhood may be determined in the womb
2. First study of its kind finds children with food allergies are often victims of bullying
3. Penn researchers identify immune cells that fight parasites may promote allergies and asthma
4. Preventing allergies
5. Just in time for spring: Scientists find the cellular on and off switch for allergies and asthma
6. Mites on hissing coackroach may benefit humans with allergies
7. Even natural perfumes may cause allergies
8. Food allergies: Overestimated and underestimated
9. New study shows soy protein lowers non-HDL cholesterol significantly more than milk protein
10. Wildflower colors tell butterflies how to do their jobs
11. Wastewater treatment lowers pathogen levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... 08, 2016 , ... KBioBox llc announced today the launch ... developed a sophisticated “3 click” gene dditing off target analysis program and a ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
Breaking Biology Technology: